MacroGenics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. 

CEO
Eric Risser
CEOEric Risser
Employees
341
Employees341
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2000
Founded2000
Employees
341
Employees341

MGNX Key Statistics

Market cap
95.20M
Market cap95.20M
Price-Earnings ratio
-1.24
Price-Earnings ratio-1.24
Dividend yield
Dividend yield
Average volume
927.52K
Average volume927.52K
High today
$1.61
High today$1.61
Low today
$1.49
Low today$1.49
Open price
$1.58
Open price$1.58
Volume
1.80M
Volume1.80M
52 Week high
$3.84
52 Week high$3.84
52 Week low
$0.9897
52 Week low$0.9897

Stock Snapshot

MacroGenics(MGNX) stock is priced at $1.51, giving the company a market capitalization of 95.2M. It carries a P/E multiple of -1.24.

During the trading session on 2025-11-14, MacroGenics(MGNX) shares reached a daily high of $1.61 and a low of $1.49. At a current price of $1.51, the stock is +1.7% higher than the low and still -5.9% under the high.

Trading activity shows a volume of 1.8M, compared to an average daily volume of 927.52K.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.84 and a low of $0.99.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.84 and a low of $0.99.

MGNX News

TipRanks 2d
Strategic Shift and Transitional Phases Lead to Hold Rating for MacroGenics

TD Cowen analyst Tara Bancroft has maintained their neutral stance on MGNX stock, giving a Hold rating today. Meet Your ETF AI Analyst Discover how TipRanks' ET...

TipRanks 2d
MacroGenics reports Q3 EPS 27c vs 90c last year

Reports Q3 revenue $72.839M vs $110.7M last year. “During the third quarter, our team aggressively advanced each of our previously outlined strategic priorities...

TipRanks 2d
MacroGenics expects cash to fund operations into late 2027

Cash Runway Guidance: MacroGenics (MGNX) anticipates that its cash, cash equivalents and marketable securities balance of $146.4 million as of September 30, 202...

Analyst ratings

71%

of 7 ratings
Buy
28.6%
Hold
71.4%
Sell
0%

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.